Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Onartuzumab plus mFOLFOX6 vs placebo plus mFOLFOX6 in HER2-negative metastatic gastroesophageal cancer
2012-001402-23Phase 3Suspended
- Sponsor
- Roche
- Start
- Jun 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of onartuzumab in esophagogastric junction cancer, gastric cancer (GC), sponsored by Roche. Started Jun 2012; status: suspended.
02
Drugs
onartuzumab
03
Conditions
esophagogastric junction cancergastric cancer (GC)
Beyond the preview
Go deeper on 2012-001402-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001402-23.